Perinodular injection of thymopentine (TP5) in cutaneous and subcutaneous metastases of melanoma

N. Cascinelli, C. Clemente, R. Bufalino, M. Baldini, L. Mascheroni, S. Zurrida, M. C. Mihm

Research output: Contribution to journalArticle

Abstract

The potential therapeutic efficacy of TP5 in patients with cutaneous and subcutaneous metastases of melanoma was tested in a double-blind study comparing the drug and placebo injected perinodularly. Of the 47 nodules present in the 16 patients treated with TP5, 24 showed a measurable response, whereas only one out of 15 nodules in patients treated with a placebo showed a minor response (P = 0.02). In two patients treated with TP5 a response of two nodules not perinodularly injected was also observed. Sclerosis, CD45RO+ cells and MIB 1 cells were more frequently observed in nodules treated with TP5 than with placebo. (P = 8 ± 10−4; 0.03 and 0.01, respectively). Evaluating the trends of these findings in nodules treated with placebo; with TP5-treated, non-responding nodules; or with TP5-treated, responding, a positive trend was observed for sclerosis and CD45RO+ cells (P = 5 ± 10−4 and 2 ± 10−3, respectively) and a negative one for MIB 1 cells (P = 2 ± 10−3). These preliminary data suggest that lymphoid cells associated with nodules regression are activated large lymphocytes (CD45RO+ and CD3). Sclerosis might be Interpreted as the final morphologic event, and reduction of proliferative activity (MIB 1 cells) as the conseqence of cytolytic action.

Original languageEnglish
Pages (from-to)471-476
Number of pages6
JournalMelanoma Research
Volume3
Issue number6
Publication statusPublished - 1993

Fingerprint

Melanoma
Neoplasm Metastasis
Sclerosis
Skin
Injections
Placebos
Lymphocytes
Double-Blind Method
Pharmaceutical Preparations
Therapeutics

Keywords

  • Local treatment
  • Metastatic melanoma
  • Perinodular injection
  • Thymopentine

ASJC Scopus subject areas

  • Cancer Research
  • Dermatology
  • Oncology

Cite this

Cascinelli, N., Clemente, C., Bufalino, R., Baldini, M., Mascheroni, L., Zurrida, S., & Mihm, M. C. (1993). Perinodular injection of thymopentine (TP5) in cutaneous and subcutaneous metastases of melanoma. Melanoma Research, 3(6), 471-476.

Perinodular injection of thymopentine (TP5) in cutaneous and subcutaneous metastases of melanoma. / Cascinelli, N.; Clemente, C.; Bufalino, R.; Baldini, M.; Mascheroni, L.; Zurrida, S.; Mihm, M. C.

In: Melanoma Research, Vol. 3, No. 6, 1993, p. 471-476.

Research output: Contribution to journalArticle

Cascinelli, N, Clemente, C, Bufalino, R, Baldini, M, Mascheroni, L, Zurrida, S & Mihm, MC 1993, 'Perinodular injection of thymopentine (TP5) in cutaneous and subcutaneous metastases of melanoma', Melanoma Research, vol. 3, no. 6, pp. 471-476.
Cascinelli N, Clemente C, Bufalino R, Baldini M, Mascheroni L, Zurrida S et al. Perinodular injection of thymopentine (TP5) in cutaneous and subcutaneous metastases of melanoma. Melanoma Research. 1993;3(6):471-476.
Cascinelli, N. ; Clemente, C. ; Bufalino, R. ; Baldini, M. ; Mascheroni, L. ; Zurrida, S. ; Mihm, M. C. / Perinodular injection of thymopentine (TP5) in cutaneous and subcutaneous metastases of melanoma. In: Melanoma Research. 1993 ; Vol. 3, No. 6. pp. 471-476.
@article{3962540998354da1ae3d58e0fbe7d42c,
title = "Perinodular injection of thymopentine (TP5) in cutaneous and subcutaneous metastases of melanoma",
abstract = "The potential therapeutic efficacy of TP5 in patients with cutaneous and subcutaneous metastases of melanoma was tested in a double-blind study comparing the drug and placebo injected perinodularly. Of the 47 nodules present in the 16 patients treated with TP5, 24 showed a measurable response, whereas only one out of 15 nodules in patients treated with a placebo showed a minor response (P = 0.02). In two patients treated with TP5 a response of two nodules not perinodularly injected was also observed. Sclerosis, CD45RO+ cells and MIB 1− cells were more frequently observed in nodules treated with TP5 than with placebo. (P = 8 ± 10−4; 0.03 and 0.01, respectively). Evaluating the trends of these findings in nodules treated with placebo; with TP5-treated, non-responding nodules; or with TP5-treated, responding, a positive trend was observed for sclerosis and CD45RO+ cells (P = 5 ± 10−4 and 2 ± 10−3, respectively) and a negative one for MIB 1 cells (P = 2 ± 10−3). These preliminary data suggest that lymphoid cells associated with nodules regression are activated large lymphocytes (CD45RO+ and CD3−). Sclerosis might be Interpreted as the final morphologic event, and reduction of proliferative activity (MIB 1− cells) as the conseqence of cytolytic action.",
keywords = "Local treatment, Metastatic melanoma, Perinodular injection, Thymopentine",
author = "N. Cascinelli and C. Clemente and R. Bufalino and M. Baldini and L. Mascheroni and S. Zurrida and Mihm, {M. C.}",
year = "1993",
language = "English",
volume = "3",
pages = "471--476",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Perinodular injection of thymopentine (TP5) in cutaneous and subcutaneous metastases of melanoma

AU - Cascinelli, N.

AU - Clemente, C.

AU - Bufalino, R.

AU - Baldini, M.

AU - Mascheroni, L.

AU - Zurrida, S.

AU - Mihm, M. C.

PY - 1993

Y1 - 1993

N2 - The potential therapeutic efficacy of TP5 in patients with cutaneous and subcutaneous metastases of melanoma was tested in a double-blind study comparing the drug and placebo injected perinodularly. Of the 47 nodules present in the 16 patients treated with TP5, 24 showed a measurable response, whereas only one out of 15 nodules in patients treated with a placebo showed a minor response (P = 0.02). In two patients treated with TP5 a response of two nodules not perinodularly injected was also observed. Sclerosis, CD45RO+ cells and MIB 1− cells were more frequently observed in nodules treated with TP5 than with placebo. (P = 8 ± 10−4; 0.03 and 0.01, respectively). Evaluating the trends of these findings in nodules treated with placebo; with TP5-treated, non-responding nodules; or with TP5-treated, responding, a positive trend was observed for sclerosis and CD45RO+ cells (P = 5 ± 10−4 and 2 ± 10−3, respectively) and a negative one for MIB 1 cells (P = 2 ± 10−3). These preliminary data suggest that lymphoid cells associated with nodules regression are activated large lymphocytes (CD45RO+ and CD3−). Sclerosis might be Interpreted as the final morphologic event, and reduction of proliferative activity (MIB 1− cells) as the conseqence of cytolytic action.

AB - The potential therapeutic efficacy of TP5 in patients with cutaneous and subcutaneous metastases of melanoma was tested in a double-blind study comparing the drug and placebo injected perinodularly. Of the 47 nodules present in the 16 patients treated with TP5, 24 showed a measurable response, whereas only one out of 15 nodules in patients treated with a placebo showed a minor response (P = 0.02). In two patients treated with TP5 a response of two nodules not perinodularly injected was also observed. Sclerosis, CD45RO+ cells and MIB 1− cells were more frequently observed in nodules treated with TP5 than with placebo. (P = 8 ± 10−4; 0.03 and 0.01, respectively). Evaluating the trends of these findings in nodules treated with placebo; with TP5-treated, non-responding nodules; or with TP5-treated, responding, a positive trend was observed for sclerosis and CD45RO+ cells (P = 5 ± 10−4 and 2 ± 10−3, respectively) and a negative one for MIB 1 cells (P = 2 ± 10−3). These preliminary data suggest that lymphoid cells associated with nodules regression are activated large lymphocytes (CD45RO+ and CD3−). Sclerosis might be Interpreted as the final morphologic event, and reduction of proliferative activity (MIB 1− cells) as the conseqence of cytolytic action.

KW - Local treatment

KW - Metastatic melanoma

KW - Perinodular injection

KW - Thymopentine

UR - http://www.scopus.com/inward/record.url?scp=0027788173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027788173&partnerID=8YFLogxK

M3 - Article

C2 - 8161886

AN - SCOPUS:0027788173

VL - 3

SP - 471

EP - 476

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 6

ER -